Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Stem Cell Therapy Doesn’t Improve Cancer Outcome
Uncategorized

Stem Cell Therapy Doesn’t Improve Cancer Outcome

By medwebJul 1, 2003
Share
Facebook Twitter Email

July 8, 2003

Stem Cell Therapy Doesn’t Improve Cancer Outcome

CHICAGO— Adding high-dose chemotherapy and bone marrow transplantation to conventional chemotherapy offers little benefit for women with primary breast cancer who are at high risk for recurrence, finds a study reported in the July 3 issue of The New England Journal of Medicine.

Moreover, toxicities from the transplantation offset any of its possible benefits, said Northwestern University’s Feinberg School of Medicine cancer researcher Martin S. Tallman, MD, one of the two senior authors on the Eastern Cooperative Oncology Group-coordinated study. Dr. Tallman’s co-senior author was Hillard M. Lazarus, MD, of Case Western Reserve University.

Results of the randomized clinical trial, which compared rates of breast cancer recurrence, disease-free survival, and overall survival, dispel a belief widely held during the 1990s that adjuvant high-dose chemotherapy with bone marrow transplant might be a viable treatment option and improve survival for women for women with aggressive, recurring breast cancers.

In the 1990s no randomized clinical trial was conducted to assess definitively the value of stem cell transplantation in breast cancer, although Phase II clinical studies and other reports suggested a three-year disease-free survival rate of about 65 to 70 percent.

The results published today were derived from data from more than 500 women with primary breast cancer with involvement of at least 10 lymph nodes under the arm who received six cycles of standard chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with or without high-dose chemotherapy and stem cell transplantation.

The study showed the addition of stem cell transplantation provided no significant improvement in either disease-free survival or overall survival in women with Stage II or III breast cancer.

Time to recurrence was longer for patients who had received stem cell transplantation; however, nine patients on the stem cell transplantation arm of the study died. An additional nine patients on this arm developed leukemia or other bone marrow disorders.

“These results were not completely surprising, since earlier studies in metastatic cancer also did not confirm a benefit,” Dr. Tallman said.

“Our major focus for patients with high-risk breast cancer now centers on exciting new drugs and combinations rather than high-dose chemotherapy and transplant,” he said.

Dr. Tallman is professor of medicine at the Feinberg School and a researcher in The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Lazarus is a researcher at Case Western Reserve University School of Medicine, Ireland Cancer Center, Cleveland.

Other investigators on the study were William J. Gradishar, MD, associate professor of medicine, Feinberg School; Robert Gray, Dana-Farber Cancer Institute, Boston; Nicholas J. Robert, MD, Inova Fairfax Hospital, Falls Church, Va.; Charles F. LeMaistre, MD, Texas Transplant Institute, San Antonio; C. Kent Osborne, MD, Breast Center, Baylor College of Medicine and Methodist Hospital, Houston; William P. Vaughan, MD, University of Alabama at Birmingham; Thomas M. Pisansky, MD, Mayo Clinic, Rochester, Minn.; John Fetting, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore; and Elisabeth Paietta, Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York.

This study was coordinated by the Eastern Cooperative Oncology Group and supported in part by grants from the U.S. Public Health Service, National Cancer Institute, National Institutes of Health, and U.S. Department of Health and Human Services.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Investigating the Connection Between Steps and Heart Disease Risk

Feb 1, 2023

Medical School Faculty Named AAAS Fellows

Jan 31, 2023

Transforming the Way Cancer Vaccines are Designed and Made

Jan 30, 2023

Calcium Channels Regulate Neuroinflammation and Neuropathic Pain 

Jan 27, 2023

Changes in Medical School Leadership

Jan 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.